Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

Summary

The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof of concept for future trials.

Timeline

Start

2021-12-14

Primary completion

2022-07-18

Completion

2022-10-11

Drugs

Indications